{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:31:25Z","timestamp":1793766685332,"version":"4.6.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023360","name":"St Vincent&apos;s Hospital Melbourne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023360","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017478","name":"Usona Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["General Hospital Psychiatry"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.genhosppsych.2025.08.001","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T15:36:10Z","timestamp":1755012970000},"page":"322-331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial"],"prefix":"10.1016","volume":"96","author":[{"given":"Margaret L.","family":"Ross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin L.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Boughey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"O'Callaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hiscock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.genhosppsych.2025.08.001_bb0005","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1470-2045(11)70002-X","article-title":"Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies","volume":"12","author":"Mitchell","year":"2011","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.genhosppsych.2025.08.001_bb0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1472-684X-13-10","article-title":"Prevalence and risk factors of depressive symptoms in a Canadian palliative home care population: a cross-sectional study","volume":"13","author":"Fisher","year":"2014","journal-title":"BMC Palliat Care"},{"key":"10.1016\/j.genhosppsych.2025.08.001_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12904-015-0067-2","article-title":"The relationship between pain management and psychospiritual distress in patients with advanced cancer following admission to a palliative care unit","volume":"14","author":"Lee","year":"2015","journal-title":"BMC Palliat Care"},{"issue":"6","key":"10.1016\/j.genhosppsych.2025.08.001_bb0020","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1200\/JCO.2011.40.8922","article-title":"Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with Cancer: systematic review and Meta-analysis","volume":"31","author":"Faller","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.genhosppsych.2025.08.001_bb0025","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/0269216317722123","article-title":"Death anxiety interventions in patients with advanced cancer: a systematic review","volume":"32","author":"Grossman","year":"2018","journal-title":"Palliat Med"},{"issue":"9369","key":"10.1016\/j.genhosppsych.2025.08.001_bb0030","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(03)13310-7","article-title":"Effect of spiritual well-being on end-of-life despair in terminally-ill cancer patients","volume":"361","author":"McClain","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.genhosppsych.2025.08.001_bb0035","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.2006.07.9046","article-title":"Religiousness and spiritual support among advanced cancer patients and associations with end-of-life treatment preferences and quality of life","volume":"25","author":"Balboni","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.genhosppsych.2025.08.001_bb0040","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/YIC.0b013e328340775e","article-title":"Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: a meta-analysis of patient characteristics and placebo response rates in randomized controlled trials","volume":"26","author":"Iovieno","year":"2011","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.genhosppsych.2025.08.001_bb0045","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/09540261.2013.842542","article-title":"Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: a review","volume":"26","author":"Grassi","year":"2014","journal-title":"Int Rev Psychiatry"},{"issue":"4","key":"10.1016\/j.genhosppsych.2025.08.001_bb0050","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1191\/0269216306pm1151oa","article-title":"The use of benzodiazepines in palliative care","volume":"20","author":"Henderson","year":"2006","journal-title":"Palliat Med"},{"issue":"1","key":"10.1016\/j.genhosppsych.2025.08.001_bb0055","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ageing\/afq140","article-title":"Which medications to avoid in people at risk of delirium: a systematic review","volume":"40","author":"Clegg","year":"2011","journal-title":"Age Ageing"},{"issue":"7","key":"10.1016\/j.genhosppsych.2025.08.001_bb0060","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1177\/0269216309107024","article-title":"European association for palliative care (EAPC) recommended framework for the use of sedation in palliative care","volume":"23","author":"Cherny","year":"2009","journal-title":"Palliat Med"},{"issue":"9","key":"10.1016\/j.genhosppsych.2025.08.001_bb0065","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.genhosppsych.2025.08.001_bb0070","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.genhosppsych.2025.08.001_bb0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage Cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"10.1016\/j.genhosppsych.2025.08.001_bb0080","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol (Oxf)"},{"issue":"12","key":"10.1016\/j.genhosppsych.2025.08.001_bb0085","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol (Oxf)"},{"issue":"2","key":"10.1016\/j.genhosppsych.2025.08.001_bb0090","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/0269881119897615","article-title":"Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer","volume":"34","author":"Agin-Liebes","year":"2020","journal-title":"J Psychopharmacol (Oxf)"},{"issue":"2","key":"10.1016\/j.genhosppsych.2025.08.001_bb0095","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/105294199277860","article-title":"The international conference on harmonization good clinical practice guideline","volume":"6","author":"Dixon","year":"1999","journal-title":"Qual Assur"},{"key":"10.1016\/j.genhosppsych.2025.08.001_bb0100","series-title":"DC Am Psychiatr Assoc","article-title":"Statistical manual of mental disorders: DSM-5 (ed.) Washington","author":"Diagnostic","year":"2013"},{"key":"10.1016\/j.genhosppsych.2025.08.001_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-684X-4-7","article-title":"The Australia-modified Karnofsky performance status (AKPS) scale: a revised scale for contemporary palliative care clinical practice","volume":"4","author":"Abernethy","year":"2005","journal-title":"BMC Palliat Care"},{"issue":"6","key":"10.1016\/j.genhosppsych.2025.08.001_bb0110","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"10.1016\/j.genhosppsych.2025.08.001_bb0115","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jpsychores.2007.01.009","article-title":"Performance of the hospital anxiety and depression scale as a screening tool for major depressive disorder in cancer patients","volume":"63","author":"Walker","year":"2007","journal-title":"J Psychosom Res"},{"issue":"6","key":"10.1016\/j.genhosppsych.2025.08.001_bb0120","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J Psychopharmacol (Oxf)"},{"key":"10.1016\/j.genhosppsych.2025.08.001_bb0125","first-page":"1541528","article-title":"Music as a collaborating actor: new insights into the nature and role of music in psychedelic-assisted psychotherapy","volume":"16","author":"Dwyer","year":"2025","journal-title":"Front Psychol"},{"key":"10.1016\/j.genhosppsych.2025.08.001_bb0130","series-title":"Manual for the Beck Depression Inventory-II","author":"Beck","year":"1996"},{"issue":"3 & 4","key":"10.1016\/j.genhosppsych.2025.08.001_bb0135","article-title":"The state-trait anxiety inventory","volume":"5","author":"Spielberger","year":"2017","journal-title":"Rev Interam Psicol J Psychol"},{"key":"10.1016\/j.genhosppsych.2025.08.001_bb0140","series-title":"Death anxiety handbook: Research, instrumentation, and application","first-page":"121","article-title":"Death attitude profile\u2014Revised: A multidimensional measure of attitudes toward death","author":"Wong","year":"2015"},{"issue":"3","key":"10.1016\/j.genhosppsych.2025.08.001_bb0145","first-page":"551","article-title":"WHO quality of life scale (WHOQOL)","volume":"28","author":"W","year":"1998","journal-title":"Psuchological Med"},{"issue":"4","key":"10.1016\/j.genhosppsych.2025.08.001_bb0150","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1468-5906.2012.01685.x","article-title":"Factor analysis of the mystical experience questionnaire: a study of experiences occasioned by the hallucinogen psilocybin","volume":"51","author":"MacLean","year":"2012","journal-title":"J Sci Study Relig"},{"key":"10.1016\/j.genhosppsych.2025.08.001_bb0155","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.genhosppsych.2025.08.001_bb0160","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1037\/a0021767","article-title":"Assessing hopelessness in terminally ill cancer patients: development of the hopelessness assessment in illness questionnaire","volume":"23","author":"Rosenfeld","year":"2011","journal-title":"Psychol Assess"},{"issue":"14","key":"10.1016\/j.genhosppsych.2025.08.001_bb0165","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/cncr.30015","article-title":"Refinement and revalidation of the demoralization scale: the DS-II\u2014internal validity","volume":"122","author":"Robinson","year":"2016","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.genhosppsych.2025.08.001_bb0170","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","article-title":"The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation","volume":"1","author":"Webster","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.genhosppsych.2025.08.001_bb0175","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0; published on November 27, 2017","author":"US Department of Health and Human Services","year":"2019"},{"issue":"188","key":"10.1016\/j.genhosppsych.2025.08.001_bb0180","first-page":"59935","article-title":"Investigational new drug safety reporting requirements for human drug and biological products and safety reporting requirements for bioavailability and bioequivalence studies in humans. Final rule","volume":"75","author":"Food and Drug Administration H","year":"2010","journal-title":"Fed Regist"},{"key":"10.1016\/j.genhosppsych.2025.08.001_bb0185","series-title":"Stata statistical software: Release 17","author":"StataCorp","year":"2021"},{"issue":"10","key":"10.1016\/j.genhosppsych.2025.08.001_bb0190","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1017\/S0033291720003700","article-title":"How much change is enough? Evidence from a longitudinal study on depression in UK primary care","volume":"52","author":"Kounali","year":"2022","journal-title":"Psychol Med"},{"issue":"3","key":"10.1016\/j.genhosppsych.2025.08.001_bb0195","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jpainsymman.2023.06.006","article-title":"Hope: a pilot study of psilocybin enhanced group psychotherapy in patients with cancer","volume":"66","author":"Lewis","year":"2023","journal-title":"J Pain Symptom Manag"},{"issue":"7","key":"10.1016\/j.genhosppsych.2025.08.001_bb0200","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/cncr.35010","article-title":"Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder","volume":"130","author":"Agrawal","year":"2024","journal-title":"Cancer"}],"container-title":["General Hospital Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834325001574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834325001574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:29:59Z","timestamp":1772810999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163834325001574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":40,"alternative-id":["S0163834325001574"],"URL":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2025.08.001","relation":{},"ISSN":["0163-8343"],"issn-type":[{"value":"0163-8343","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"General Hospital Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2025.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}